Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing. Guidance development process Early value assessment (EVA) guidance rapidly provides recommendations on promising health technologies that have the potential to address national unmet need. NICE has assessed early evidence on these technologies to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated. The diagnostics advisory committee has considered the evidence and the views of clinical and patient experts. This topic is part of the pilot using the new EVA approach. How we develop NICE early value assessment guidance